• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

In vitro-in vivo relationship of oral extended-release dosage forms.

作者信息

Liu F Y, Sambol N C, Giannini R P, Liu C Y

机构信息

Impax Pharmaceuticals, Fremont, California 94539, USA.

出版信息

Pharm Res. 1996 Oct;13(10):1501-6. doi: 10.1023/a:1016023428028.

DOI:10.1023/a:1016023428028
PMID:8899841
Abstract

PURPOSE

A method to establish the in vitro-in vivo relationship of oral extended-release products is proposed.

METHODS

The approach utilizes incremental amounts of drug released and absorbed within defined time intervals, to construct a chi2 distributed variable for testing in vitro-in vivo similarity.

RESULTS

A case study is used to demonstrate that the similarities between incremental values of in vivo absorbed and in vivo dissolved fractions are distinguishable for different dissolution profiles despite naturally significant linear correlations between cumulative in vivo absorbed and in vitro dissolved fractions (with different dissolution tests) of an oral extended-release product.

CONCLUSIONS

The method enables investigators to compare different in vitro dissolution profiles of an oral extended-release product to find an optimized dissolution profile to be the surrogate of the in vivo release process of the product.

摘要

相似文献

1
In vitro-in vivo relationship of oral extended-release dosage forms.
Pharm Res. 1996 Oct;13(10):1501-6. doi: 10.1023/a:1016023428028.
2
Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.开发一种用于设计缓释口服剂型的具有生理相关性的群体药代动力学体外-体内相关性方法。
Mol Pharm. 2017 Jan 3;14(1):53-65. doi: 10.1021/acs.molpharmaceut.6b00677. Epub 2016 Dec 12.
3
Pharmacokinetics of oral extended-release dosage forms. I. Release kinetics, concentration, and absorbed fraction.
Pharm Res. 1995 May;12(5):720-8. doi: 10.1023/a:1016215827004.
4
In vitro-in vivo relationships for oral extended-release drug products.口服缓释制剂的体外-体内相关性
J Biopharm Stat. 1997 Nov;7(4):565-78. doi: 10.1080/10543409708835207.
5
In Vitro-In Vivo Predictive Dissolution-Permeation-Absorption Dynamics of Highly Permeable Drug Extended-Release Tablets via Drug Dissolution/Absorption Simulating System and pH Alteration.通过药物溶解/吸收模拟系统和 pH 值改变预测高渗透性药物缓释片的体外-体内预测溶解-渗透-吸收动力学。
AAPS PharmSciTech. 2018 May;19(4):1882-1893. doi: 10.1208/s12249-018-0996-1. Epub 2018 Apr 16.
6
In vivo evaluation of controlled-release products.
J Pharm Sci. 1993 Nov;82(11):1145-50. doi: 10.1002/jps.2600821116.
7
In vitro-in vivo correlation and dissolution studies with oral theophylline dosage forms.
J Pharm Sci. 1985 Feb;74(2):161-4. doi: 10.1002/jps.2600740211.
8
Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms.药物性质与制剂对口服缓释剂型体外药物释放及生物豁免法规的影响
AAPS J. 2016 Mar;18(2):333-45. doi: 10.1208/s12248-015-9861-2. Epub 2016 Jan 14.
9
Convolution-based approaches for in vivo-in vitro correlation modeling.基于卷积的体内-体外相关性建模方法。
Adv Exp Med Biol. 1997;423:53-65. doi: 10.1007/978-1-4684-6036-0_5.
10
In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.健康志愿者中,来自双峰释放制剂的哌甲酯的体外溶出和体内口服吸收情况。
Biopharm Drug Dispos. 2004 Mar;25(2):91-8. doi: 10.1002/bdd.390.

引用本文的文献

1
In vitro and in vivo evaluation of single-unit commercial conventional tablet and sustained-release capsules compared with multiple-unit polystyrene microparticle dosage forms of Ibuprofen.布洛芬单剂量单位市售普通片剂和缓释胶囊与多剂量单位聚苯乙烯微粒剂型的体外和体内评价
AAPS PharmSciTech. 2006 Sep 1;7(3):72. doi: 10.1208/pt070372.

本文引用的文献

1
In vivo/in vitro correlation of experimental sustained-release theophylline formulations.
Pharm Res. 1993 Apr;10(4):588-92. doi: 10.1023/a:1018910421840.
2
In vitro-in vivo correlation for modified-release formulations.缓释制剂的体外-体内相关性
J Pharm Sci. 1993 Feb;82(2):132-7. doi: 10.1002/jps.2600820204.
3
In vitro-in vivo correlation of a modified-release oral form of ketotifen: in vitro dissolution rate specification.富马酸酮替芬缓释口服制剂的体外-体内相关性:体外溶出度标准
J Pharm Sci. 1994 Feb;83(2):131-6. doi: 10.1002/jps.2600830205.
4
Pharmacokinetics of oral extended-release dosage forms. I. Release kinetics, concentration, and absorbed fraction.
Pharm Res. 1995 May;12(5):720-8. doi: 10.1023/a:1016215827004.
5
Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.
Pharm Res. 1990 Nov;7(11):1167-71. doi: 10.1023/a:1015988410977.
6
Correlation of in vitro release rate and in vivo absorption characteristics of four chlorpheniramine maleate extended-release formulations.
Pharm Res. 1992 Apr;9(4):450-6. doi: 10.1023/a:1015823926152.